INBX has done something remarkable in the past month: it has more than doubled, rising 115% to $134.35 while carrying more than a quarter of its free float in short positions. That combination — a heavily shorted small-cap biotech running hard into its May 15 earnings call — defines the tension this week.
The short side of the trade is materially underwater. Short interest runs at 26.2% of free float, up from around 24.3% in early April when the stock was closer to $60. Shorts added exposure through April 10 as the price climbed, and that position has barely moved since — a sign that most short-holders are sitting on significant losses rather than covering. Borrowing costs tell a different story from the pressure implied by a squeeze: cost to borrow has actually eased to 0.78% from over 1% three weeks ago, and lending availability is ample. There is no mechanical squeeze forcing shorts out. They are choosing to hold, or cannot exit at scale without moving the price further.
Options positioning is where the most interesting new signal sits. The put/call ratio jumped to 0.31 on Friday — more than 2.4 standard deviations above its 20-day average of 0.18. That is the most defensive reading in months for a stock whose options market has been almost exclusively call-dominated all year. The shift is small in absolute terms (PCR remains low), but the acceleration from 0.12 in mid-April to 0.31 in three weeks is notable. Someone is paying for downside protection at elevated premiums, right ahead of a catalyst.
The Street is sparsely covered and leaning cautious. Stifel initiated with a Buy and a $150 target in early April — but that was when the stock was trading near $60, and the price has now blown through that level. The single available mean target of $300 implies substantial further upside at the current price; however, with only one actionable recent rating and a stock that has moved this aggressively, the Street is effectively watching rather than guiding. The ORTEX short score of 67.8 places INBX well above the median for short-side pressure, though the score has eased from a recent high of 74.8 on April 29. On factor rankings, INBX scores in only the 12th percentile on short-score positioning — meaning most stocks in the universe carry lower short-side risk. For a stock up 115% in a month, that is the tension: fundamental bulls can point to a clear Sanofi stake of nearly 8% (held steady at 1.16 million shares) and Perceptive Advisors building to 9.9%, while bears are underwriting a story where the move has outrun the data.
Earnings on May 15 are the forcing function. The past four prints produced moves of -0.4%, -11.3%, +1.5%, and +3.7% on the day respectively, and -10.0%, -4.2%, +5.4%, and +12.5% over the following week. The directional pattern is genuinely mixed — there is no consistent post-print bias either way. What makes this print different is the setup: a stock up 115% in 30 days, with 26% of the float short, defensive options positioning picking up, and a heavily concentrated institutional register. Whether the upcoming report resolves the standoff between trapped shorts and momentum holders is the single most important thing to watch in the days ahead.
See the live data behind this article on ORTEX.
Open INBX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
